Submit a Letter to the Editor for:

HTLV-1 propels untransformed CD4⁺ lymphocytes into the cell cycle while protecting CD8⁺ cells from death

David Sibon, Anne-Sophie Gabet, Marc Zandecki, Christiane Pinatel, Julien Thête, Marie-Hélène Delfau-Larue, Samira Rabaaoui, Antoine Gessain, Olivier Gout, Steven Jacobson, Franck Mortreux, Eric Wattel

Published in Volume 116, Issue 4

J Clin Invest. 2006; 116(4):974 doi:10.1172/JCI27198

Abstract | Full text | PDF

H uman T cell leukemia virus type 1 (HTLV-1) infects both CD4⁺ and CD8⁺ lymphocytes, yet it induces adult T cell leukemia/lymphoma (ATLL) that is regularly of the CD4⁺ phenotype. Here we show that in vivo infected CD4⁺ and CD8⁺ T cells displayed similar patterns of clonal expansion in carriers without malignancy. Cloned infected cells from individuals without malignancy had a dramatic increase in spontaneous proliferation, which predominated in CD8⁺ lymphocytes and depended on the amount of tax mRNA. In fact, the clonal expansion of HTLV-1–positive CD8⁺ and CD4⁺ lymphocytes relied on 2 distinct mechanisms — infection prevented cell death in the former while recruiting the latter into the cell cycle. Cell cycling, but not apoptosis, depended on the level of viral-encoded tax expression. Infected tax-expressing CD4⁺ lymphocytes accumulated cellular defects characteristic of genetic instability. Therefore, HTLV-1 infection establishes a preleukemic phenotype that is restricted to CD4⁺ infected clones.

Guidelines: The Editorial Board will only consider letters that we deem relevant and of interest to our readers. We will not post data that have not been subjected to peer review, nor will we post letters that are essentially a reiteration of another letter. All accepted letters will be posted on our website within one week of acceptance. The Editors reserve the right to edit any letter for length, content, and clarity. Authors of all accepted letters will be asked to preview any changes. Authors will be notified by e-mail if their letters were not accepted. As this is a final decision, no appeals will be considered. Specific requirements: All letters must be 400 words or fewer. You may enter the letter as plain text or HTML, if you wish. The author's name and e-mail address are required, and will be posted with the letter. All possible conflicts of interest must be noted, even if they are not posted. If you wish to include a figure (keep in mind that non-peer-reviewed data will not be posted), please contact the editor directly at editors@the-jci.org.